COVID-19 oral drug significantly reduces infection mortality in the elderly
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
COVID-19 oral drug significantly reduces infection mortality in the elderly
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The Lancet: COVID-19 oral drug significantly reduces infection mortality in the elderly.
On October 8, The Lancet published an article “Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study”, which is the largest real-world study on the effectiveness of two COVID-19 oral drugs in the treatment of Omicron variant strain infection.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
The research data comes from 1,074,856 community-infected patients in Hong Kong in 2022.
After screening, 4,983 molnupiravir users and 5,542 Paxlovid users were included in the statistics, of which 9,176 were older than 60 years old (87.1%) and completed the full course of vaccination. of only 2,650 (22.4%) .
That is to say, most of them belong to the high-risk group of COVID-19 infection – advanced age and unvaccinated.
The study found that the use of two COVID-19 drugs in the early stage of infection can significantly reduce the risk of disease progression and death in the elderly. Among them, the COVID-19 oral drug Paxlovid reduced the risk of death after hospitalization in the elderly by 79%.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.